Injectable medicines, the sterile drugs delivered by syringe or drip in hospitals, are among the hardest to manufacture and, for years, among the most profitable to sell. Hikma Pharmaceuticals (LSE:HIK) built much of its reputation on them, but its latest results show that even this prized Business is not immune to competition.

Half-year figures published on 6 August 2026 revealed a group leaning on its other divisions while injectables paused for breath.

Three businesses under one roof

Hikma spans three segments: Injectables sold in the United States, Europe and the Middle East; a US generics arm, Hikma Rx; and a Branded business selling patented and generic medicines across the Middle East and North Africa. That spread gives it both the high margins of complex injectables and the geographic resilience of its home-region branded operation.

The company's edge in injectables lies in the difficulty of making them: sterile Manufacturing is capital-intensive and tightly regulated, which limits competition and supports pricing, at least until rivals eventually arrive.

Persistent shortages of hospital injectables in the United States have played to Hikma's strengths, since a manufacturer that can reliably Supply a scarce sterile drug commands both Volume and price. The group has invested to expand capacity and to add more complex products, including its own take on high-demand treatments, to stay ahead of generic competitors.

Its Middle East and North Africa heritage is a further differentiator. Hikma is a leading pharmaceutical name across the region, with local manufacturing and distribution that would be hard for a newcomer to replicate, giving the Branded division a defensive, fast-growing base.

Branded strength offsets an injectables pause

Group core Revenue rose 4% to $1,728m in the first half, with core operating profit up 9% to $405m and core Earnings Per Share up 5% to 128 cents. The Branded division led the way, with revenue up 15% to $502m and operating profit up 23%, on a Margin of 32.5%.

Injectables, however, were flat at $685m in revenue, with operating profit down 8% as competition weighed, though the margin remained a healthy 27.6%. US generics revenue was also flat at $520m but profit rose 16%. The Interim Dividend increased 6% to 38 cents, and the company repurchased $227m of shares under a $250m programme.

The risks around the growth

Injectables face steady competitive pressure as other manufacturers win approvals for the same products, which can erode both price and volume, precisely the trend visible in the latest profit dip. US generics remain exposed to pricing deflation, a long-running feature of that market.

Hikma held its full-year guidance, expecting group revenue growth of 2% to 4% and core operating profit of $720m to $770m, a relatively cautious outlook that reflects these headwinds. Regulatory and manufacturing risks are ever-present for a company whose products must meet exacting sterility standards.

What to watch next

Investors should watch competition in key injectable products, the durability of the fast-growing Branded business, and whether US generics pricing stabilises. Progress on new product launches and any bolt-on acquisitions will shape the medium-term growth rate.

Hikma's diversified structure did its Job in the first half, with branded strength cushioning a softer injectables performance. The business remains solidly profitable and cash-generative, but the results are a reminder that even a hard-to-copy speciality eventually attracts competitors, keeping management under pressure to renew its pipeline. For a defensive, income-paying stock, Hikma offers a reasonable and dependable blend of growth and resilience, with the fast-rising Branded arm increasingly doing the heavy lifting. The key uncertainty is injectables, once the group's growth engine and now its softest spot; whether management can refresh that pipeline and win the next wave of complex approvals will largely determine how quickly the whole company can grow from here.